Home › Funds › DEERFIELD MANAGEMENT COMPANY, L.P. › SPRY
DEERFIELD MANAGEMENT COMPANY, L.P. position in SPRY
ARS PHARMACEUTICALS INC · Health Care
DEERFIELD MANAGEMENT COMPANY, L.P. reported holding 7,503,812 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$60.1M, representing 0.75% of its reported portfolio and ranking #35 among its reported holdings. DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DEERFIELD MANAGEMENT COMPANY, L.P.'s SPRY position evolved
DEERFIELD MANAGEMENT COMPANY, L.P. first disclosed a stake in SPRY in Q3 2023 at 11,077,927 shares (US$41.9M). The position peaked in Q2 2025 at 9,724,508 shares, worth US$169.7M. Across 12 filings, DEERFIELD MANAGEMENT COMPANY, L.P. increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 7,503,812 shares valued at US$60.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 11.08M | $41.87M | New |
| Q4 2023 | 11.08M | $60.71M | Hold |
| Q1 2024 | 11.08M | $113.22M | Hold |
| Q2 2024 | 11.08M | $94.27M | Hold |
| Q3 2024 | 11.08M | $160.63M | Hold |
| Q4 2024 | 10.51M | $110.93M | Reduce |
| Q1 2025 | 10.51M | $132.27M | Hold |
| Q2 2025 | 9.72M | $169.69M | Reduce |
| Q3 2025 | 7.50M | $75.41M | Reduce |
| Q4 2025 | 7.50M | $87.42M | Hold |
| Q1 2026 | 7.50M | $60.26M | Hold |
| Q2 2026 | 7.50M | $60.11M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- ORBIMED ADVISORS LLC 8.29M sh · $66.39M · Q2 2026
- Tyro Capital Management LLC 4.46M sh · $35.72M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $32.14M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M sh · $9.08M · Q2 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K sh · $4.86M · Q2 2026
More on DEERFIELD MANAGEMENT COMPANY, L.P.
FAQ
How long has DEERFIELD MANAGEMENT COMPANY, L.P. held SPRY?
DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s current position in SPRY?
As of Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. holds 7.50M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $60.11M, representing 0.75% of its reported portfolio and ranking #35.
Has DEERFIELD MANAGEMENT COMPANY, L.P. been buying or selling SPRY?
In the latest 13F filing (Q2 2026), DEERFIELD MANAGEMENT COMPANY, L.P. held unchanged its position in SPRY. The position peaked in Q2 2025 at 9.72M shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.